Lotus Pharmaceuticals Stock Performance
| LTUS Stock | USD 0.01 0 28.57% |
Lotus Pharmaceuticals holds a performance score of 6 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.83, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Lotus Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Lotus Pharmaceuticals is likely to outperform the market. Use Lotus Pharmaceuticals downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on Lotus Pharmaceuticals.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Lotus Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Lotus Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -29.4 M |
Lotus |
Lotus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.43 in Lotus Pharmaceuticals on January 25, 2024 and sell it today you would earn a total of 0.07 from holding Lotus Pharmaceuticals or generate 16.28% return on investment over 90 days. Lotus Pharmaceuticals is currently generating 1.307% in daily expected returns and assumes 15.3211% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Lotus, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lotus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lotus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Lotus Pharmaceuticals, and traders can use it to determine the average amount a Lotus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0853
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LTUS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.32 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.31 actual daily | 25 75% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Lotus Pharmaceuticals is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lotus Pharmaceuticals by adding it to a well-diversified portfolio.
Lotus Pharmaceuticals Fundamentals Growth
Lotus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Lotus Pharmaceuticals, and Lotus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lotus Pink Sheet performance.
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0456 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 762.17 K | |||
| Shares Outstanding | 27.82 M | |||
| Price To Earning | 0.18 X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 72.7 M | |||
| EBITDA | 10.31 M | |||
| Cash And Equivalents | 158.91 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 5.24 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | 3.58 X | |||
| Cash Flow From Operations | 26.78 M | |||
| Earnings Per Share | 0.06 X | |||
| Total Asset | 103.18 M | |||
| Retained Earnings | 65 M | |||
| Current Asset | 8 M | |||
| Current Liabilities | 14 M | |||
About Lotus Pharmaceuticals Performance
To evaluate Lotus Pharmaceuticals Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Lotus Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Lotus Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Lotus Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Lotus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the Peoples Republic of China. Lotus Pharmaceutical operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 233 people.Things to note about Lotus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Lotus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Lotus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lotus Pharmaceuticals is way too risky over 90 days horizon | |
| Lotus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Lotus Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| The company currently holds 5.24 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Lotus Pharmaceuticals has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Lotus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Lotus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lotus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lotus to invest in growth at high rates of return. When we think about Lotus Pharmaceuticals' use of debt, we should always consider it together with cash and equity. |
- Analyzing Lotus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lotus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Lotus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lotus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lotus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lotus Pharmaceuticals' pink sheet. These opinions can provide insight into Lotus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lotus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Lotus Pink Sheet analysis
When running Lotus Pharmaceuticals' price analysis, check to measure Lotus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceuticals is operating at the current time. Most of Lotus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lotus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets |